CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The CellMate project aims to develop a blood-based test for early cancer detection and minimal residual disease monitoring. Utilizing advanced technology, it seeks to provide rapid and accurate results, significantly improving patient outcomes and reducing healthcare costs associated with cancer treatment.
With over 10M deaths and an annual cost of €199B, cancer poses an immense burden on individuals, healthcare, and society.
To reduce cancer deaths, improve patients’ quality of life, and lower the economic cost, both early detection and treatment are key.
Current methods for early cancer screening and minimal residual disease (MRD) testing include inconvenient and costly procedures such as mammograms, Pap smears, colonoscopies.
Unfortunately, for the majority of cancers, no early detection method…
UNIVERSITÄTSKLINIKUM SCHLESWIG-HOLSTEIN
UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Kiel
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Denmark, Aarhus
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Sweden, Solna
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
